Ampio Pharmaceuticals (Ampio Pharmaceuticals) Cash And Cash Equivalents : $4.09 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Ampio Pharmaceuticals Cash And Cash Equivalents?

Ampio Pharmaceuticals's quarterly cash and cash equivalents declined from Jun. 2023 ($6.95 Mil) to Sep. 2023 ($6.40 Mil) but then stayed the same from Sep. 2023 ($6.40 Mil) to Dec. 2023 ($4.09 Mil).

Ampio Pharmaceuticals's annual cash and cash equivalents declined from Dec. 2021 ($33.89 Mil) to Dec. 2022 ($12.65 Mil) and declined from Dec. 2022 ($12.65 Mil) to Dec. 2023 ($4.09 Mil).

Ampio Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for Ampio Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ampio Pharmaceuticals Cash And Cash Equivalents Chart

Ampio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

6.53

17.35

33.89

12.65

4.09

Ampio Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															12.65	10.35	6.95	6.40	4.09

Ampio Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Ampio Pharmaceuticals (OTCPK:AMPE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Ampio Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Ampio Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Ampio Pharmaceuticals (Ampio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ampio Pharmaceuticals Inc (OTCPK:AMPE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

373 Inverness Parkway, Suite 200, Englewood, CO, USA, 80112

Website

https://www.ampiopharma.com

Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the clinical development of Ampion and preclinical development. Its product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19-induced respiratory distress.

Executives

J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Michael A Martino	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
David R Stevens	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Elizabeth Varki Jobes	director	640 LEE ROAD, CHESTERBROOK PA 19087
Philip H Coelho	director	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Holli Cherevka	officer: Chief Operating Officer	C/O AMPIO PHARMACEUTICALS, INC., 373 IVERNESS PARKWAY, ENGLEWOOD CO 80112
Dan Stokely	officer: CFO	4810 EASTGATE MALL, SAN DIEGO CA 92121
Chilcott, Iii Thomas E.	officer: Chief Financial Officer	373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Gregory A Gould	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Joshua R. Disbrow	officer: Chief Operating Officer	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Michael Macaluso	director	C/O AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Richard B Giles	director	5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
David Bar-or	director, officer: Chief Scientific Officer	C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Vaughan Lennox Clift	officer: Chief Regulatory Affairs	807 NOBLE SPRINGS ROAD, HOUSTON TX 77062
Mark D Mcgregor	officer: Chief Financial Officer	5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111